المؤلفون: Lasky-Su, J, Himes, BE, Raby, BA, Klanderman, BJ, Sylvia, JS, Lange, C, Melen, E, Martinez, FD, Israel, E, Gauderman, J, Gilliland, F, Sleiman, P, Hakonarson, H, Celedon, JC, Soto-Quiros, M, Avila, L, Lima, JJ, Irvin, CG, Peters, SP, Boushey, H, Chinchilli, VM, Mauger, D, Tantisira, K, Weiss, ST

المصدر: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 42(12):1724-1733

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:125805239Test

المؤلفون: Bijlani, A, Mauger, D, Goodheart, C, dOrsay, G, Suman, J

المصدر: European Journal of Public Health ; volume 33, issue Supplement_2 ; ISSN 1101-1262 1464-360X

مصطلحات موضوعية: Public Health, Environmental and Occupational Health

الوصف: Background Asthma impacts 334 million people globally. Medication adherence is estimated at 50% worldwide. Digital therapeutics (DTx) may improve medication adherence and health outcomes. Methods Prospective, single cohort observational study of 104 adults with asthma managed on inhaled corticosteroids. Subjects had 90-day access to Aptar Digital Health respiratory platform: HeroTracker to monitor adherence, spirometer for lung function, and BreatheSmart mobile app with real-time alerts. Primary outcomes: asthma control, rescue medication use. Secondary outcomes: controller medication adherence, patient feedback. Results Subjects completed Asthma Control Test (ACT) at baseline (T0); 96% (N = 100) completed ACT at 90 days (T1). Between T0 and T1, ACT scores increased significantly (baseline: 16.5 ± 4.7; ΔT0 to T1: + 2.8, 95% CI (2.0, 3.6), p-value <0.001); rescue medication use decreased 44% ((95% CI: 14.1, 63.5), p-value = 0.008); adherence to controller medication decreased 10.7% ((95% CI: 6.4, 15.1), p-value <0.001). 82.5% of subjects reported platform very/somewhat easy to use, 97.5% rated spirometer very/somewhat easy to use, 92.5% reported alerts very/somewhat helpful. Platform rating mean score = 7.825/10 (1-10; 10=high). Conclusions DTx may improve asthma control and decrease rescue medication use. T1 medication adherence was 17% higher than global medication adherence. Patient feedback was positive. References 1. Enilari, O., Sinha, S. (2019). The global impact of asthma in adult populations. Ann Glob Health, 85(1), 2, 1-7. 2. Kim, J., et al. (2018). Medication adherence: the elephant in the room. US Pharm, 43, 1, 30-34. Key messages • DTx promoted improvement in ACT scores and decreased rescue medication use. • DTx platform feedback was positive.

الإتاحة: https://doi.org/10.1093/eurpub/ckad160.823Test
https://academic.oup.com/eurpub/article-pdf/33/Supplement_2/ckad160.823/52418442/ckad160.823.pdfTest

المؤلفون: Martineau, AR, Jolliffe, DA, Greenberg, L, Aloia, JF, Bergman, P, Dubnov-Raz, G, Esposito, S, Ganmaa, D, Ginde, AA, Goodall, EC, Grant, CC, Janssens, W, Jensen, ME, Kerley, CP, Laaksi, I, Manaseki-Holland, S, Mauger, D, Murdoch, DR, Neale, R, Rees, JR, Simpson, S, Stelmach, I, Kumar, GT, Urashima, M, Camargo, CA, Griffiths, CJ, Hooper, RL

المصدر: Health technology assessment (Winchester, England). 23(2):1

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:140130309Test

المؤلفون: Wang, Y, Tong, C, Wang, Z, Mauger, D, Tantisira, KG, Israel, E, Szefler, SJ, Chinchilli, VM, Boushey, HA, Lazarus, SC, Lemanske, RF, Wu, R

المصدر: The Pharmacogenomics Journal. 15(5)

مصطلحات موضوعية: Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Asthma, Clinical Trials and Supportive Activities, Human Genome, Lung, Genetics, Clinical Research, Respiratory, Adult, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Glucocorticoids, Humans, Male, Pharmacogenetics, Polymorphism, Single Nucleotide, Pharmacology & Pharmacy, Pharmacology and pharmaceutical sciences

الوصف: Asthma is a chronic lung disease that has a high prevalence. The therapeutic intervention of this disease can be made more effective if genetic variability in patients' response to medications is implemented. However, a clear picture of the genetic architecture of asthma intervention response remains elusive. We conducted a genome-wide association study (GWAS) to identify drug response-associated genes for asthma, in which 909 622 SNPs were genotyped for 120 randomized participants who inhaled multiple doses of glucocorticoids. By integrating pharmacodynamic properties of drug reactions, we implemented a mechanistic model to analyze the GWAS data, enhancing the scope of inference about the genetic architecture of asthma intervention. Our pharmacodynamic model observed associations of genome-wide significance between dose-dependent response to inhaled glucocorticoids (measured as %FEV1) and five loci (P=5.315 × 10(-7) to 3.924 × 10(-9)), many of which map to metabolic genes related to lung function and asthma risk. All significant SNPs detected indicate a recessive effect, at which the homozygotes for the mutant alleles drive variability in %FEV1. Significant associations were well replicated in three additional independent GWAS studies. Pooled together over these three trials, two SNPs, chr6 rs6924808 and chr11 rs1353649, display an increased significance level (P=6.661 × 10(-16) and 5.670 × 10(-11)). Our study reveals a general picture of pharmacogenomic control for asthma intervention. The results obtained help to tailor an optimal dose for individual patients to treat asthma based on their genetic makeup.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/44r1f8trTest

المؤلفون: Choi, T. (Timothy), Devries, M. (Mark), Bacharier, L. B. (Leonard B.), Busse, W. (William), Camargo, C. A. (Carlos A., Jr.), Cohen, R. (Robyn), Demuri, G. P. (Gregory P.), Evans, M. D. (Michael D.), Fitzpatrick, A. M. (Anne M.), Gergen, P. J. (Peter J.), Grindle, K. (Kristine), Gruchalla, R. (Rebecca), Hartert, T. (Tina), Hasegawa, K. (Kohei), Hershey, G. K. (Gurjit K. Khurana), Holt, P. (Patrick), Homil, K. (Kiara), Jartti, T. (Tuomas), Kattan, M. (Meyer), Kercsmar, C. (Carolyn), Kim, H. (Haejin), Laing, I. A. (Ingrid A.), LeBeau, P. (Petra), Lee, K. E. (Kristine E.), Le Souef, P. N. (Peter N.), Liu, A. (Andrew), Mauger, D. T. (David T.), Ober, C. (Carole), Pappas, T. (Tressa), Patel, S. J. (Shilpa J.), Phipatanakul, W. (Wanda), Pongracic, J. (Jacqueline), Seroogy, C. (Christine), Sly, P. D. (Peter D.), Tisler, C. (Christopher), Wald, E. R. (Ellen R.), Wood, R. (Robert), Gangnon, R. (Ronald), Jackson, D. J. (Daniel J.), Lemanske, R. F. (Robert F., Jr.), Gern, J. E. (James E.), Bochkov, Y. A. (Yury A.)

مصطلحات موضوعية: CDHR3, epidemiology, genetics, rhinovirus, wheezing

الوصف: Rationale: Rhinovirus (RV) C can cause asymptomatic infection and respiratory illnesses ranging from the common cold to severe wheezing. Objectives: To identify how age and other individual-level factors are associated with susceptibility to RV-C illnesses. Methods: Longitudinal data from the COAST (Childhood Origins of Asthma) birth cohort study were analyzed to determine relationships between age and RV-C infections. Neutralizing antibodies specific for RV-A and RV-C (three types each) were determined using a novel PCR-based assay. Data were pooled from 14 study cohorts in the United States, Finland, and Australia, and mixed-effects logistic regression was used to identify factors related to the proportion of RV-C versus RV-A detection. Measurements and Main Results: In COAST, RV-A and RV-C infections were similarly common in infancy, whereas RV-C was detected much less often than RV-A during both respiratory illnesses and scheduled surveillance visits (P < 0.001, χ²) in older children. The prevalence of neutralizing antibodies to RV-A or RV-C types was low (5–27%) at the age of 2 years, but by the age of 16 years, RV-C seropositivity was more prevalent (78% vs. 18% for RV-A; P < 0.0001). In the pooled analysis, the RV-C to RV-A detection ratio during illnesses was significantly related to age (P < 0.0001), CDHR3 genotype (P < 0.05), and wheezing illnesses (P < 0.05). Furthermore, certain RV types (e.g., C2, C11, A78, and A12) were consistently more virulent and prevalent over time. Conclusions: Knowledge of prevalent RV types, antibody responses, and populations at risk based on age and genetics may guide the development of vaccines or other novel therapies against this important respiratory pathogen.

وصف الملف: application/pdf

العلاقة: info:eu-repo/semantics/altIdentifier/pissn/1073-449X; info:eu-repo/semantics/altIdentifier/eissn/1535-4970

الإتاحة: http://urn.fi/urn:nbn:fi-fe2022033025997Test

المؤلفون: Jonkman N. H., Colpo M., Klenk J., Todd C., Hoekstra T., Del Panta V., Rapp K., Van Schoor N. M., Bandinelli S., Heymans M. W., Mauger D., Cattelani L., Denkinger M. D., Rothenbacher D., Helbostad J. L., Vereijken B., Maier A. B., Pijnappels M.

المساهمون: Jonkman N.H., Colpo M., Klenk J., Todd C., Hoekstra T., Del Panta V., Rapp K., Van Schoor N.M., Bandinelli S., Heymans M.W., Mauger D., Cattelani L., Denkinger M.D., Rothenbacher D., Helbostad J.L., Vereijken B., Maier A.B., Pijnappels M.

مصطلحات موضوعية: Active aging, Functioning, Individual patient data, Middle aged, Personalised care, Preventive medicine, Activities of Daily Living, Aged, Cardiovascular Disease, Chronic Disease, Cognitive Dysfunction, Cohort Studie, Depression, Female, Follow-Up Studie, Germany, Hand Strength, Human, Independent Living, Italy, Male, Netherland, Predictive Value of Test, Risk Factor, United Kingdom, Walking Speed

الوصف: Background: Identifying those people at increased risk of early functional decline in activities of daily living (ADL) is essential for initiating preventive interventions. The aim of this study is to develop and validate a clinical prediction model for onset of functional decline in ADL in three years of follow-up in older people of 65-75 years old. Methods: Four population-based cohort studies were pooled for the analysis: ActiFE-ULM (Germany), ELSA (United Kingdom), InCHIANTI (Italy), LASA (Netherlands). Included participants were 65-75 years old at baseline and reported no limitations in functional ability in ADL at baseline. Functional decline was assessed with two items on basic ADL and three items on instrumental ADL. Participants who reported at least some limitations at three-year follow-up on any of the five items were classified as experiencing functional decline. Multiple logistic regression analysis was used to develop a prediction model, with subsequent bootstrapping for optimism-correction. We applied internal-external cross-validation by alternating the data from the four cohort studies to assess the discrimination and calibration across the cohorts. Results: Two thousand five hundred sixty community-dwelling people were included in the analyses (mean age 69.7 ± 3.0 years old, 47.4% female) of whom 572 (22.3%) reported functional decline at three-year follow-up. The final prediction model included 10 out of 22 predictors: age, handgrip strength, gait speed, five-repeated chair stands time (non-linear association), body mass index, cardiovascular disease, diabetes, chronic obstructive pulmonary disease, arthritis, and depressive symptoms. The optimism-corrected model showed good discrimination with a C statistic of 0.72. The calibration intercept was 0.06 and the calibration slope was 1.05. Internal-external cross-validation showed consistent performance of the model across the four cohorts. Conclusions: Based on pooled cohort data analyses we were able to show that the onset of functional decline ...

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31248370; info:eu-repo/semantics/altIdentifier/wos/WOS:000473140200001; volume:19; issue:1; firstpage:1; lastpage:12; numberofpages:12; journal:BMC GERIATRICS; info:eu-repo/grantAgreement/EC/H2020/689238; http://hdl.handle.net/11585/888371Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85068254022; https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-019-1192-1Test

الإتاحة: https://doi.org/10.1186/s12877-019-1192-1Test
http://hdl.handle.net/11585/888371Test

المؤلفون: Martineau, AR, Jolliffe, DA, Hooper, RL, Greenberg, L, Aloia, JF, Bergman, P, Dubnov-Raz, G, Esposito, S, Ganmaa, D, Ginde, AA, Goodall, EC, Grant, CC, Griffiths, CJ, Janssens, W, Laaksi, I, Manaseki-Holland, S, Mauger, D, Murdoch, DR, Neale, R, Rees, JR, Simpson, S, Stelmach, I, Kumar, GT, Urashima, M, Camargo, CA

المصدر: BMJ (Clinical research ed.). 356:i6583

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:135239920Test

المؤلفون: Jonkman, NH, Colpo, M, Klenk, J, Todd, C, Hoekstra, T, Del Panta, V, Rapp, K, van Schoor, NM, Bandinelli, S, Heymans, MW, Mauger, D, Cattelani, L, Denkinger, MD, Rothenbacher, D, Helbostad, JL, Vereijken, B, Maier, AB, Pijnappels, M

الوصف: BACKGROUND: Identifying those people at increased risk of early functional decline in activities of daily living (ADL) is essential for initiating preventive interventions. The aim of this study is to develop and validate a clinical prediction model for onset of functional decline in ADL in three years of follow-up in older people of 65-75 years old. METHODS: Four population-based cohort studies were pooled for the analysis: ActiFE-ULM (Germany), ELSA (United Kingdom), InCHIANTI (Italy), LASA (Netherlands). Included participants were 65-75 years old at baseline and reported no limitations in functional ability in ADL at baseline. Functional decline was assessed with two items on basic ADL and three items on instrumental ADL. Participants who reported at least some limitations at three-year follow-up on any of the five items were classified as experiencing functional decline. Multiple logistic regression analysis was used to develop a prediction model, with subsequent bootstrapping for optimism-correction. We applied internal-external cross-validation by alternating the data from the four cohort studies to assess the discrimination and calibration across the cohorts. RESULTS: Two thousand five hundred sixty community-dwelling people were included in the analyses (mean age 69.7 ± 3.0 years old, 47.4% female) of whom 572 (22.3%) reported functional decline at three-year follow-up. The final prediction model included 10 out of 22 predictors: age, handgrip strength, gait speed, five-repeated chair stands time (non-linear association), body mass index, cardiovascular disease, diabetes, chronic obstructive pulmonary disease, arthritis, and depressive symptoms. The optimism-corrected model showed good discrimination with a C statistic of 0.72. The calibration intercept was 0.06 and the calibration slope was 1.05. Internal-external cross-validation showed consistent performance of the model across the four cohorts. CONCLUSIONS: Based on pooled cohort data analyses we were able to show that the onset of functional decline ...

العلاقة: pii: 10.1186/s12877-019-1192-1; Jonkman, N. H., Colpo, M., Klenk, J., Todd, C., Hoekstra, T., Del Panta, V., Rapp, K., van Schoor, N. M., Bandinelli, S., Heymans, M. W., Mauger, D., Cattelani, L., Denkinger, M. D., Rothenbacher, D., Helbostad, J. L., Vereijken, B., Maier, A. B. & Pijnappels, M. (2019). Development of a clinical prediction model for the onset of functional decline in people aged 65-75 years: pooled analysis of four European cohort studies. BMC GERIATRICS, 19 (1), https://doi.org/10.1186/s12877-019-1192-1Test.; http://hdl.handle.net/11343/249824Test

الإتاحة: https://doi.org/10.1186/s12877-019-1192-1Test
http://hdl.handle.net/11343/249824Test

المؤلفون: Weisskopf M. C., Soffitta P., Baldini L., Ramsey B. D., O'Dell S. L., Romani R. W., Matt G., Deininger W. D., Baumgartner W. H., Bellazzini R., Costa E., Kolodziejczak J. J., Latronico L., Marshall H. L., Muleri F., Bongiorno S. D., Tennant A., Bucciantini N., Dovciak M., Marin F., Marscher A., Poutanen J., Slane P., Turolla R., Kalinowski W., Di Marco A., Fabiani S., Minuti M., La Monaca F., Pinchera M., Rankin J., Sgro' C., Trois A., Xie F., Alexander C., Allen D. Z., Amici F., Andersen J., Antonelli A., Antoniak S., Attina P., Barbanera M., Bachetti M., Baggett R. M., Bladt J., Brez A., Bonino R., Boree C., Borotto F., Breeding S., Brienza D., Bygott H. K., Caporale C., Cardelli C., Carpentiero R., Castellano S., Castronuovo M., Cavalli L., Cavazzuti E., Ceccanti M., Centrone M., Citraro S., D'Amico F., D'Alba E., Di Gesu L., Del Monte E., Dietz K. L., Di Lalla N., Persio G. D., Dolan D., Donnarumma I., Evangelista Y., Ferrant K., Ferrazzoli R., Ferrie M., Footdale J., Forsyth B., Foster M., Garelick B., Gunji S., Gurnee E., Head M., Hibbard G., Johnson S., Kelly E., Kilaru K., Lefevre C., Roy S. L., Loffredo P., Lorenzi P., Lucchesi L., Maddox T., Magazzu G., Maldera S., Manfreda A., Mangraviti E., Marengo M., Marrocchesi A., Massaro F., Mauger D., McCracken J., McEachen M., Mize R., Mereu P., Mitchell S., Mitsuishi I., Morbidini A., Mosti F., Nasimi H., Negri B., Negro M., Nguyen T., Nitschke I., Nuti A., Onizuka M., Oppedisano C., Orsini L., Osborne D., Pacheco R., Paggi A., Painter W., Pavelitz S. D., Pentz C., Piazzolla R., Perri M., Pesce-Rollins M., Peterson C., Pilia M., Profeti A., Puccetti S., Ranganathan J., Ratheesh A., Reedy L., Root N., Rubini A., Ruswick S., Sanchez J., Sarra P., Santoli F., Scalise E., Sciortino A., Schroeder C., Seek T., Sosdian K., Spandre G., Speegle C. O., Tamagawa T., Tardiola M., Tobia A., Thomas N. E., Valerie R., Vimercati M., Walden A. L., Weddendorf B., Wedmore J., Welch D., Zanetti D., Zanetti F.

المساهمون: Weisskopf, M. C., Soffitta, P., Baldini, L., Ramsey, B. D., O'Dell, S. L., Romani, R. W., Matt, G., Deininger, W. D., Baumgartner, W. H., Bellazzini, R., Costa, E., Kolodziejczak, J. J., Latronico, L., Marshall, H. L., Muleri, F., Bongiorno, S. D., Tennant, A., Bucciantini, N., Dovciak, M., Marin, F., Marscher, A., Poutanen, J., Slane, P., Turolla, R., Kalinowski, W., Di Marco, A., Fabiani, S., Minuti, M., La Monaca, F., Pinchera, M., Rankin, J., Sgro', C., Trois, A., Xie, F., Alexander, C., Allen, D. Z., Amici, F., Andersen, J., Antonelli, A., Antoniak, S., Attina, P., Barbanera, M., Bachetti, M., Baggett, R. M., Bladt, J., Brez, A., Bonino, R., Boree, C., Borotto, F., Breeding, S., Brienza, D., Bygott, H. K., Caporale, C., Cardelli, C., Carpentiero, R., Castellano, S., Castronuovo, M., Cavalli, L., Cavazzuti, E., Ceccanti, M., Centrone, M., Citraro, S., D'Amico, F., D'Alba, E., Di Gesu, L., Del Monte, E., Dietz, K. L., Di Lalla, N., Persio, G. D., Dolan, D., Donnarumma, I., Evangelista, Y., Ferrant, K., Ferrazzoli, R., Ferrie, M., Footdale, J., Forsyth, B., Foster, M., Garelick, B., Gunji, S., Gurnee, E., Head, M., Hibbard, G., Johnson, S., Kelly, E., Kilaru, K., Lefevre, C., Roy, S. L., Loffredo, P., Lorenzi, P., Lucchesi, L., Maddox, T., Magazzu, G., Maldera, S., Manfreda, A., Mangraviti, E., Marengo, M., Marrocchesi, A., Massaro, F., Mauger, D.

مصطلحات موضوعية: x-ray polarimetry, gas pixel detector, grazing-incidence optic, Astrophysics - Instrumentation and Methods for Astrophysics

الوصف: Launched on 2021 December 9, the Imaging X-ray Polarimetry Explorer (IXPE) is a NASA Small Explorer Mission in collaboration with the Italian Space Agency (ASI). The mission will open a new window of investigation—imaging x-ray polarimetry. The observatory features three identical telescopes, each consisting of a mirror module assembly with a polarization-sensitive imaging x-ray detector at the focus. A coilable boom, deployed on orbit, provides the necessary 4-m focal length. The observatory utilizes a three-axis-stabilized spacecraft, which provides services such as power, attitude determination and control, commanding, and telemetry to the ground. During its 2-year baseline mission, IXPE will conduct precise polarimetry for samples of multiple categories of x-ray sources, with follow-on observations of selected targets.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000834667000026; volume:8; issue:2; journal:JOURNAL OF ASTRONOMICAL TELESCOPES, INSTRUMENTS, AND SYSTEMS; http://hdl.handle.net/11590/414967Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85132870319

الإتاحة: https://doi.org/10.1117/1.JATIS.8.2.026002Test
http://hdl.handle.net/11590/414967Test

المؤلفون: Jolliffe, DA, Greenberg, L, Hooper, RL, Griffiths, CJ, Camargo, CA, Kerley, CP, Jensen, ME, Mauger, D, Stelmach, I, Urashima, M, Martineau, AR

مصطلحات موضوعية: Adolescent, Adrenal Cortex Hormones, Adult, Aged, 80 and over, Anti-Asthmatic Agents, Asthma, Child, Preschool, Dietary Supplements, Disease Progression, Female, Humans, Male, Middle Aged, Secondary Prevention, Treatment Outcome, Vitamin D, Vitamins, Young Adult

الوصف: BACKGROUND: A previous aggregate data meta-analysis of randomised controlled trials showed that vitamin D supplementation reduces the rate of asthma exacerbations requiring treatment with systemic corticosteroids. Whether this effect is restricted to patients with low baseline vitamin D status is unknown. METHODS: For this systematic review and one-step and two-step meta-analysis of individual participant data, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science for double-blind, placebo-controlled, randomised controlled trials of vitamin D3 or vitamin D2 supplementation in people with asthma that reported incidence of asthma exacerbation, published between database inception and Oct 26, 2016. We analysed individual participant data requested from the principal investigator for each eligible trial, adjusting for age and sex, and clustering by study. The primary outcome was the incidence of asthma exacerbation requiring treatment with systemic corticosteroids. Mixed-effects regression models were used to obtain the pooled intervention effect with a 95% CI. Subgroup analyses were done to determine whether effects of vitamin D on risk of asthma exacerbation varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration, age, ethnic or racial origin, body-mass index, vitamin D dosing regimen, use of inhaled corticosteroids, or end-study 25(OH)D levels; post-hoc subgroup analyses were done according to sex and study duration. This study was registered with PROSPERO, number CRD42014013953. FINDINGS: Our search identified 483 unique studies, eight of which were eligible randomised controlled trials (total 1078 participants). We sought individual participant data for each and obtained it for seven studies (955 participants). Vitamin D supplementation reduced the rate of asthma exacerbation requiring treatment with systemic corticosteroids among all participants (adjusted incidence rate ratio [aIRR] 0·74, 95% CI 0·56-0·97; p=0·03; 955 participants in seven ...

وصف الملف: 881 - 890

العلاقة: Lancet Respir Med; http://qmro.qmul.ac.uk/xmlui/handle/123456789/26923Test

الإتاحة: https://doi.org/10.1016/S2213-2600Test(17)30306-5
http://qmro.qmul.ac.uk/xmlui/handle/123456789/26923Test